NCT04308889 is a EARLY_PHASE1 clinical trial of Lovaza in Inflammation; Skin, sponsored by Brigham and Women's Hospital.

Who is sponsoring NCT04308889?

NCT04308889 is sponsored by Brigham and Women's Hospital.

What drugs are being tested in NCT04308889?

Interventions in NCT04308889: Lovaza, Cantharone, Phlebotomy.

What condition does NCT04308889 study?

NCT04308889 studies Inflammation; Skin, Resolution, Blister.

Is NCT04308889 still recruiting?

NCT04308889 is currently completed. Last updated 26 May 2022.

Last reviewed 2022-05-26 · How we verify

NCT04308889

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pro-Resolving Mediators in Acute Inflammation in Humans

Completed EARLY_PHASE1 Last updated 26 May 2022

What this trial tests

EARLY_PHASE1 trial testing Lovaza in Inflammation; Skin in 19 participants. Completed in 22 February 2022.

Timeline

2 July 2018

Primary endpoint
3 February 2022

22 February 2022

Quick facts

Lead sponsor	Brigham and Women's Hospital
Phase	EARLY_PHASE1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	crossover
Masking	none
Primary purpose	basic science
Enrollment	19
Start date	2 July 2018
Primary completion	3 February 2022
Estimated completion	22 February 2022
Sites	1 location across United States

Drugs / interventions tested

Lovaza — full drug profile →
Cantharone
Phlebotomy

Conditions studied

Inflammation; Skin — all drugs for Inflammation; Skin →
Resolution — all drugs for Resolution →
Blister — all drugs for Blister →

Sponsor

Brigham and Women's Hospital

Who can join

Adults 18 to 64, any sex, with Inflammation; Skin or Resolution. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators are undertaking a clinical blister model with or without dietary supplementation with omega-3 fatty acids (i.e., Lovaza) to determine the role of specialized pro-resolving mediators - endogenous lipids converted from omega-3 fatty acid precursors including those in Lovaza - on inflammation parameters and their resolution.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Regulation of T-Cell Immune Responses by Pro-Resolving Lipid Mediators.
Perez-Hernandez J, Chiurchiù V, Perruche S, You S. · · 2021 · cited 33× · PMID 34868025 · DOI 10.3389/fimmu.2021.768133
Specialized Pro-Resolving Lipid Mediators: Endogenous Roles and Pharmacological Activities in Infections.
Rasquel-Oliveira FS, Silva MDVD, Martelossi-Cebinelli G, Fattori V, et al · · 2023 · cited 23× · PMID 37446699 · DOI 10.3390/molecules28135032
Fa(c)t checking: How fatty acids shape metabolism and function of macrophages and dendritic cells.
Almeida L, Everts B. · · 2021 · cited 13× · PMID 33788250 · DOI 10.1002/eji.202048944
Pro-resolving lipid mediators in diseases: exploring the molecular basis and clinical implication.
Li C, Wang Z, Yang Y, Jiang Q, et al · · 2026 · PMID 41486400 · DOI 10.1186/s43556-025-00400-5

Verify or expand the search:

Other trials of Lovaza

Trials testing the same drug.

NCT05281562 — Immunonutrition for Diabetic Foot Ulcers · Phase 2, PHASE3 · terminated

Other Brigham and Women's Hospital trials

Trials by the same sponsor.

NCT07011758 — Dynamic Treatment Regimes for Opioid Use Disorder · Phase 2 · not yet recruiting
NCT06310018 — Augmented Ultrasound-Facilitated, Catheter-Directed Fibrinolysis for PE · suspended
NCT04519177 — Randomized Trial of a Sleep Disorders Program on Firefighter Safety and Disability ... · NA · not yet recruiting
NCT06355986 — Computerized Decision Support to Prevent Stroke in Atrial Fibrillation · NA · not yet recruiting
NCT06099275 — Evaluation of Hemodynamics in People With Untreated Preeclampsia Using Echocardiography · suspended

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04308889 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Brigham and Women's Hospital
Last refreshed: 26 May 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04308889.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing